Yang H, Testa JR, Carbone M (2008) Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 9:147–157

Article  PubMed  PubMed Central  Google Scholar 

Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–65

Article  CAS  PubMed  Google Scholar 

Thomas R, Francis R, Davies HE, Lee YC (2014) Interventional therapies for malignant pleural effusions: the present and the future. Respirology 19:809–822

Article  PubMed  Google Scholar 

Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW (2003) Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 126(1):11–16

Article  PubMed  Google Scholar 

Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker DJ (2011) FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging 38:810–821

Article  PubMed  Google Scholar 

Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S et al (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24:4587–93

Article  PubMed  Google Scholar 

Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J et al (2010) A Novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging and clinical parameters. Clin Cancer Res 16:2409–2417

Article  CAS  PubMed  Google Scholar 

Lopci E (2025) Current status of staging and restaging malignant pleural mesothelioma. Semin Nucl Med 55:240–251

Article  PubMed  Google Scholar 

Kwek BH, Aquino SL, Fischman AJ (2004) Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 125:2356–2360

Article  PubMed  Google Scholar 

Weiss N, Solomon SB (2003) Talc pleurodesis mimics pleural metastases: differentiation with positron emission tomography/computed tomography. Clin Nucl Med 28:811–814

Article  PubMed  Google Scholar 

Nguyen NC, Tran I, Hueser CN, Oliver D, Farghaly HR, Osman MM (2009) F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med 34:886–890

Article  PubMed  Google Scholar 

Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42:432–45

CAS  PubMed  Google Scholar 

Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T et al (2011) L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res 31:4075–4082

PubMed  Google Scholar 

Ceresoli GL, Chiti A, Santoro A (2007) 11C-labeled methionine and evaluation of malignant pleural mesothelioma. N Engl J Med 357:1982–1984

Article  CAS  PubMed  Google Scholar 

Vandemoortele T, Laroumagne S, Roca E, Bylicki O, Dales JP, Dutau H, Astoul P (2014) Positive FDG-PET/CT of the pleura twenty years after talc pleurodesis: three cases of benign talcoma. Respiration 87(3):243–248

Article  PubMed  Google Scholar 

Gorospe Sarasúa L, Jover-Díaz R, Arrieta P (2017) Intense pleural FDG uptake 12 years after talc pleurodesis: PET/CT findings. Arch Bronconeumol 53(11):638

Article  PubMed  Google Scholar 

Soltermann A, Opitz I, Burger IA (2021) Histology of the pleural rind at [18F]FDG PET/CT hot and cold spots in mesothelioma patients after talc pleurodesis and neoadjuvant chemotherapy. Pathol Res Pract 228:153660

Article  CAS  PubMed  Google Scholar 

Lopci E, Castello A, Mansi L (2022) FDG PET/CT for staging and restaging malignant mesothelioma. Semin Nucl Med 52(6):806–815

Article  PubMed  Google Scholar 

Lopci E, Novellis P, Testori A, Rahal D, Voulaz E, Bottoni E et al (2019) In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nucl Med Commun 40:1179–1186

Article  CAS  PubMed  Google Scholar 

Nishii R, Higashi T, Kagawa S, Kishibe Y, Takahashi M, Yamauchi H et al (2013) Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies. Ann Nucl Med 27(9):808–21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ (2008) The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Ann Nucl Med 22(6):533–538

Article  PubMed  Google Scholar 

Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H et al (2012) Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med 53(8):1253–61

Article  CAS  PubMed  Google Scholar 

May IJ, Nowak AK, Francis RJ, Ebert MA, Dhaliwal SS (2024) The prognostic value of F18 fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - a prospective cohort study. J Med Imaging Radiat Oncol 68(1):57–66

Article  PubMed  Google Scholar 

Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E et al (2017) Clinical staging of malignant pleural mesothelioma: current perspectives. Lung Cancer (Auckl) 8:127–139

PubMed  PubMed Central  Google Scholar 

Lopci E, Kobe C, Gnanasegaran G, Adam JA, de Geus-Oei LF (2021) PET/CT variants and pitfalls in lung cancer and mesothelioma. Semin Nucl Med 51:458–473

Article  PubMed  Google Scholar 

Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L et al (2015) Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging 42:667–75

Article  PubMed  Google Scholar 

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 World Health Organization classification of tumours of the lung, pleura, thymus, and heart. J Thorac Oncol 10:1240–1242

Article  PubMed  Google Scholar 

Galateau-Salle F, Churg A, Roggli V, Travis WD, World Health Organization Committee for Tumours of the Pleura (2016) The 2015 World Health Organization classification of tumours of the pleura: advances since the 2004 classification. J Thorac Oncol 11:142–54

Article  PubMed  Google Scholar 

Barbetakis N, Asteriou C, Papadopoulou F, Samanidis G, Paliouras D, Kleontas A et al (2010) Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg 5:27

Article  PubMed  PubMed Central  Google Scholar 

Ulaner GA, Lyall A (2013) Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. Radiographics 33:1817–1834

Article  PubMed  Google Scholar 

Niccoli-Asabella A, Notaristefano A, Rubini D, Altini C, Ferrari C, Merenda N et al (2013) 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up). Clin Imaging 37:1098–1103

Article  PubMed  Google Scholar 

Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM et al (2010) Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 17:2787–2794

Article  PubMed  Google Scholar 

Abakay A, Komek H, Abakay O, Palanci Y, Ekici F, Tekbas G et al (2013) Relationship between 18FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci 17:1233–1241

CAS  PubMed  Google Scholar 

K